Multi-Institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early-Stage Oropharyngeal Cancer (RTOG 00-22)

Journal Article · Thu Apr 15 04:00:00 EDT 2010 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2009.04.011· OSTI ID:21372195

Eisbruch, Avraham ^[1]; Harris, Jonathan ^[2]; Garden, Adam S; Chao, Clifford K.S. ^[3]; Straube, William ^[4]; Harari, Paul M ^[5]; Sanguineti, Giuseppe ^[6]; Jones, Christopher U ^[7]; Bosch, Walter R ^[4]; Ang, K Kian ^[3]

---

1. University of Michigan, Ann Arbor, MI (United States)
2. Department of Statistics, American College of Radiology (United States)
3. M.D. Anderson Cancer Center, Houston, TX (United States)
4. Image-Guided Therapy Center at Washington University, St. Louis, MO (United States)
5. University of Wisconsin, Madison, WI (United States)
6. University of Texas Medical Branch, Galveston, TX (United States)
7. Radiation Oncology Center, Sacramento, CA (United States)

Purpose: To assess the results of a multi-institutional study of intensity-modulated radiation therapy (IMRT) for early oropharyngeal cancer. Patients and Methods: Patients with oropharyngeal carcinoma Stage T1-2, N0-1, M0 requiring treatment of the bilateral neck were eligible. Chemotherapy was not permitted. Prescribed planning target volumes (PTVs) doses to primary tumor and involved nodes was 66 Gy at 2.2 Gy/fraction over 6 weeks. Subclinical PTVs received simultaneously 54-60 Gy at 1.8-2.0 Gy/fraction. Participating institutions were preapproved for IMRT, and quality assurance review was performed by the Image-Guided Therapy Center. Results: 69 patients were accrued from 14 institutions. At median follow-up for surviving patients (2.8 years), the 2-year estimated local-regional failure (LRF) rate was 9%. 2/4 patients (50%) with major underdose deviations had LRF compared with 3/49 (6%) without such deviations (p = 0.04). All cases of LRF, metastasis, or second primary cancer occurred among patients who were current/former smokers, and none among patients who never smoked. Maximal late toxicities Grade >=2 were skin 12%, mucosa 24%, salivary 67%, esophagus 19%, osteoradionecrosis 6%. Longer follow-up revealed reduced late toxicity in all categories. Xerostomia Grade >=2 was observed in 55% of patients at 6 months but reduced to 25% and 16% at 12 and 24 months, respectively. In contrast, salivary output did not recover over time. Conclusions: Moderately accelerated hypofractionatd IMRT without chemotherapy for early oropharyngeal cancer is feasible, achieving high tumor control rates and reduced salivary toxicity compared with similar patients in previous Radiation Therapy Oncology Group studies. Major target underdose deviations were associated with higher LRF rate.

• OSTI ID: 21372195
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 5 Vol. 76; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BODY
CARCINOMAS
DIGESTIVE SYSTEM
DISEASES
ESOPHAGUS
GLANDS
MEDICINE
MEMBRANES
MUCOUS MEMBRANES
NEOPLASMS
NUCLEAR MEDICINE
ORGANS
PHARYNX
RADIOLOGY
RADIOTHERAPY
RESPIRATORY SYSTEM
SALIVARY GLANDS
SKIN
THERAPY
TOXICITY